{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:22:46Z","timestamp":1792873366002,"version":"4.5.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Inflammation and platelet aggregation and activation are key processes in the initiation of a cardiovascular event. Patients with metabolic syndrome have a high risk of cardiovascular events. This study determined whether small and medium doses of aspirin have anti-inflammation and antiplatelet aggregation effects in patients with metabolic syndrome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>One hundred and twenty-one consecutive patients with metabolic syndrome were randomized into three groups, receiving 100 mg\/day of aspirin, 300 mg\/day of aspirin or a placebo, respectively, for 2 weeks. The blood levels of thromboxane B2 (TXB2), a stable product of the platelet aggregation mediator TXA2, 6-keto-prostaglandin F1-\u03b1 (6-keto-PGF1-\u03b1), a stable product of the endogenous cyclooxygenase metabolite prostaglandin I2, and inflammatory mediators including high-sensitivity C-reactive protein (hs-CRP), tumour necrosis factor-\u03b1 (TNF-\u03b1) and interleukin-6 (IL-6), were determined by ELISA and radioimmunoassay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The blood levels of hs-CRP, TNF-\u03b1, IL-6 and TXB2 were significantly decreased after 2 weeks of treatment with 300 mg\/day of aspirin. Patients who received 100 mg\/day of aspirin had decreased blood levels of hs-CRP and TXB2. The blood level of IL-6 in the 300 mg\/day aspirin group was significantly lower than that in the other two groups after 2 weeks of therapy. Aspirin at either dose did not affect the blood level of 6-keto-PGF1-\u03b1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Aspirin at all doses suppresses the blood levels of inflammatory markers and the platelet aggregation mediator TXA2 in Chinese patients with metabolic syndrome. Since the suppression induced by 300 mg\/day of aspirin was greater than that induced by 100 mg\/day of aspirin, these data suggest that 300 mg\/day of aspirin may be beneficial in decreasing the risk of cardiovascular events in Chinese patients with metabolic syndrome.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1211\/jpp.61.11.0010","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T12:25:50Z","timestamp":1287059150000},"page":"1505-1510","source":"Crossref","is-referenced-by-count":41,"title":["Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome"],"prefix":"10.1093","volume":"61","author":[{"given":"Xiu-ren","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandar M","family":"Adhikari","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-yun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-gang","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-sheng","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-yu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, First Affiliated Hospital, Zhong-Shan University , Guangzhou,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-yi","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Virginia , Charlottesville, VA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,11,1]]},"reference":[{"key":"2024103109370863400_cit1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"2024103109370863400_cit2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1203\/01.PDR.0000119367.21770.D7","article-title":"Clinical features of the metabolic syndrome in adolescents: minor role of the Trp64Arg beta3-adrenergic receptor gene variant","volume":"55","author":"Porto","year":"2004","journal-title":"Pediatr Res"},{"key":"2024103109370863400_cit3","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMoa031049","article-title":"Obesity and the metabolic syndrome in children and adolescents","volume":"350","author":"Weiss","year":"2004","journal-title":"N Engl J Med"},{"key":"2024103109370863400_cit4","first-page":"13S","article-title":"[Diabetes and multimetabolic syndrome]","volume":"47","author":"Avogaro","year":"2003","journal-title":"Ital Heart J"},{"key":"2024103109370863400_cit5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0024-3205(03)00646-5","article-title":"A major health hazard: the metabolic syndrome","volume":"73","author":"Isomaa","year":"2003","journal-title":"Life Sci"},{"key":"2024103109370863400_cit6","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1161\/hc4101.097520","article-title":"Treatment of isolated systolic hypertension is most effective in older patients with high-risk profile","volume":"104","author":"Ferrucci","year":"2001","journal-title":"Circulation"},{"key":"2024103109370863400_cit7","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2337\/diacare.28.9.2289","article-title":"The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"28","author":"Kahn","year":"2005","journal-title":"Diabetes Care"},{"key":"2024103109370863400_cit8","first-page":"888","article-title":"Importance of hypertension as a major risk factor in cardiovascular disease","volume-title":"Physiology and Treatment","author":"Kannel","year":"1977"},{"key":"2024103109370863400_cit9","first-page":"e873","article-title":"Primary prevention of ischemic stroke: a guideline from the American Heart Association\/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group","volume":"113","author":"Goldstein","year":"2006","journal-title":"Circulation"},{"key":"2024103109370863400_cit10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1210\/jc.2006-0513","article-title":"Metabolic syndrome: a multiplex cardiovascular risk factor","volume":"92","author":"Grundy","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2024103109370863400_cit11","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1467-789X.2005.00221.x","article-title":"Diagnosis and management of the metabolic syndrome in obesity","volume":"6","author":"Liberopoulos","year":"2005","journal-title":"Obes Rev"},{"key":"2024103109370863400_cit12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/oby.2004.24","article-title":"A novel pathway to the manifestations of metabolic syndrome","volume":"12","author":"Sonnenberg","year":"2004","journal-title":"Obes Res"},{"key":"2024103109370863400_cit13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"2024103109370863400_cit14","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1172\/JCI117936","article-title":"Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance","volume":"95","author":"Hotamisligil","year":"1995","journal-title":"J Clin Invest"},{"key":"2024103109370863400_cit15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1067\/mlc.2002.121552","article-title":"Effects of TNF-alpha on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations","volume":"139","author":"Porter","year":"2002","journal-title":"J Lab Clin Med"},{"key":"2024103109370863400_cit16","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1136\/hrt.69.1_Suppl.S38","article-title":"Immune and inflammatory mechanisms in the development of atherosclerosis","volume":"69","author":"Hansson","year":"1993","journal-title":"Br Heart J"},{"key":"2024103109370863400_cit17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0167-5273(93)90053-J","article-title":"Tumor necrosis factor-alpha as a myocardial depressant substance","volume":"42","author":"Odeh","year":"1993","journal-title":"Int J Cardiol"},{"key":"2024103109370863400_cit18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1046\/j.1365-2796.1999.00490.x","article-title":"The role of TNFalpha and TNF receptors in obesity and insulin resistance","volume":"245","author":"Hotamisligil","year":"1999","journal-title":"J Intern Med"},{"key":"2024103109370863400_cit19","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1054\/mehy.1997.0684","article-title":"Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline","volume":"52","author":"McCarty","year":"1999","journal-title":"Med Hypotheses"},{"key":"2024103109370863400_cit20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"2024103109370863400_cit21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"2024103109370863400_cit22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/01.CIR.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women","volume":"107","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"2024103109370863400_cit23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.CIR.0000052617.91920.FD","article-title":"C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis","volume":"107","author":"Devaraj","year":"2003","journal-title":"Circulation"},{"key":"2024103109370863400_cit24","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1161\/01.CIR.103.9.1194","article-title":"C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis","volume":"103","author":"Zwaka","year":"2001","journal-title":"Circulation"},{"key":"2024103109370863400_cit25","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1161\/01.CIR.0000093381.57779.67","article-title":"Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"},{"key":"2024103109370863400_cit26","first-page":"179","article-title":"Fasting insulin, adiponectin, hs-CRP levels, and the components of metabolic syndrome","volume":"38","author":"Adam","year":"2006","journal-title":"Acta Med Indones"},{"key":"2024103109370863400_cit27","article-title":"Pathophysiology and clinical recognition","volume-title":"Cardiovascular Medicine","author":"Willerson","year":"1995"},{"key":"2024103109370863400_cit28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.pharmthera.2006.08.005","article-title":"From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention","volume":"113","author":"Chapman","year":"2007","journal-title":"Pharmacol Ther"},{"key":"2024103109370863400_cit29","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"2024103109370863400_cit30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","article-title":"Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force","volume":"136","author":"Hayden","year":"2002","journal-title":"Ann Intern Med"},{"key":"2024103109370863400_cit31","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","article-title":"AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee","volume":"106","author":"Pearson","year":"2002","journal-title":"Circulation"},{"key":"2024103109370863400_cit32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Collaboration","year":"2002","journal-title":"BMJ"},{"key":"2024103109370863400_cit33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome - a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"2024103109370863400_cit34","first-page":"156","article-title":"The suggestion of metabolic syndrome of Diabetes Branch Association in Chinese Medical Association","volume":"12","author":"Metabolic Syndrome Trialists' Collaboration of Chinese Diabetes Association.","year":"2004","journal-title":"Clinical Journal of Diabetes"},{"key":"2024103109370863400_cit35","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/diacare.23.8.1108","article-title":"The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes","volume":"23","author":"Gabir","year":"2000","journal-title":"Diabetes Care"},{"key":"2024103109370863400_cit36","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1161\/01.CIR.96.8.2751","article-title":"Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"96","author":"Hennekens","year":"1997","journal-title":"Circulation"},{"key":"2024103109370863400_cit37","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ecl.2004.03.015","article-title":"Management of metabolic syndrome: aspirin","volume":"33","author":"Shields","year":"2004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2024103109370863400_cit38","first-page":"II2","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"2024103109370863400_cit39","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/hrt.2003.015164","article-title":"Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor","volume":"90","author":"Ikonomidis","year":"2004","journal-title":"Heart"},{"key":"2024103109370863400_cit40","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1161\/01.CIR.100.8.793","article-title":"Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin","volume":"100","author":"Ikonomidis","year":"1999","journal-title":"Circulation"},{"key":"2024103109370863400_cit41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1463-1326.2007.00794.x","article-title":"Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial","volume":"10","author":"Hovens","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"2024103109370863400_cit42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heart.83.3.361","article-title":"The pathophysiology of acute coronary syndromes","volume":"83","author":"Davies","year":"2000","journal-title":"Heart"},{"key":"2024103109370863400_cit43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM199201233260406","article-title":"The pathogenesis of coronary artery disease and the acute coronary syndromes (1)","volume":"326","author":"Fuster","year":"1992","journal-title":"N Engl J Med"},{"key":"2024103109370863400_cit44","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","article-title":"Pathophysiology of coronary artery disease","volume":"111","author":"Libby","year":"2005","journal-title":"Circulation"},{"key":"2024103109370863400_cit45","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis - an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"2024103109370863400_cit46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1477-9560-1-2","article-title":"Acute coronary disease athero-inflammation: therapeutic approach","volume":"1","author":"Altman","year":"2003","journal-title":"Thromb J"},{"key":"2024103109370863400_cit47","first-page":"2113","article-title":"Antiplatelet agents","volume-title":"Hemostasis, Thrombosis, Fibrinolysis, and Cardiovascular Disease","author":"Schafer","year":"2001"},{"key":"2024103109370863400_cit48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration","volume":"308","author":"Antiplatelet collaborative overview of randomised trials of antiplatelet therapy - I","year":"1994","journal-title":"BMJ"},{"key":"2024103109370863400_cit49","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","article-title":"An update on aspirin in the primary prevention of cardiovascular disease","volume":"163","author":"Eidelman","year":"2003","journal-title":"Arch Intern Med"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1211%2Fjpp.61.11.0010","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/61\/11\/1505\/60257164\/jpp.61.11.0010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/61\/11\/1505\/60257164\/jpp.61.11.0010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T09:55:15Z","timestamp":1730368515000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/61\/11\/1505\/6135849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,1]]},"references-count":49,"aliases":["10.1211\/jpp\/61.11.0010"],"journal-issue":{"issue":"11","published-online":{"date-parts":[[2009,11,1]]},"published-print":{"date-parts":[[2009,11,1]]}},"URL":"https:\/\/doi.org\/10.1211\/jpp.61.11.0010","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,11]]},"published":{"date-parts":[[2009,11,1]]}}}